Clinical InvestigationValvular and Congenital Heart DiseaseEffect of rosuvastatin on C-reactive protein and progression of aortic stenosis
Section snippets
Study population
The ASTRONOMER trial was a multicenter, randomized, placebo-controlled, double-blind study that assessed the effect of intensive lipid lowering using rosuvastatin 40 mg daily on the progression of AS in patients with mild to moderate AS (peak velocity 2.5-4.0 m/s). Patients with any clinical indications for lipid lowering therapy were excluded from the trial. The trial design, baseline patient characteristics, and main results of the trial have been previously described.19, 20 In brief, 269
Baseline characteristics
The clinical characteristics and biochemical measurements of the 260 patients divided into the 3 CRP tertiles are shown in Table I, and the echocardiographic findings, in Table II. Multiple regression showed that age, female gender, BMI, and low high-density lipoprotein (HDL) cholesterol were associated with elevated CRP measurements (Table III). On the other hand, there was no significant relationship between severity of AS and baseline CRP levels (Figure 1). Aortic valve morphology (bicuspid
Discussion
C-reactive protein is an inflammatory biomarker that has been shown to provide incremental predictive value in determining future cardiac events independent of conventional atherosclerotic risk factors.8, 9, 10 The recently published JUPITER study showed that treatment of apparently healthy individuals without hyperlipidemia but with elevated CRP (≥2 mg/L) can reduce cardiovascular events.23 The inflammatory process has been shown to be operative in the development of AS.3, 4, 5, 6, 7
References (31)
- et al.
Burden of valvular heart diseases: a population-based study
Lancet
(2006) - et al.
Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample
J Am Coll Cardiol
(1993) - et al.
Accumulation of T lymphocytes and expression of interleukin-2 receptors in nonrheumatic stenotic aortic valves
J Am Coll Cardiol
(1994) - et al.
Correlation of high sensitivity C-reactive protein and calcific aortic valve disease
Mayo Clin Proc
(2007) - et al.
Relation of circulating C-reactive protein to progression of aortic valve stenosis
Am J Cardiol
(2006) - et al.
Inflammation, infection, and aortic valve sclerosis; Insights from the Olmsted County (Minnesota) population
Atherosclerosis
(2004) - et al.
C-reactive protein is increased in patients with degenerative aortic valvular stenosis
J Am Coll Cardiol
(2001) - et al.
C-reactive protein predicts severity, progression, and prognosis of asymptomatic aortic valve stenosis
Am Heart J
(2008) - et al.
Prognosis and risk factors in patients with asymptomatic aortic stenosis and their modulation by atorvastatin (20 mg)
Am J Cardiol
(2008) - et al.
Astronomer investigators. Rationale, design, and baseline characteristics of a randomized trial to assess the effect of cholesterol lowering on the progression of aortic stenosis: the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial
Am Heart J
(2007)
Echocardiography assessment of left ventricular hypertrophy: comparison to necropsy findings
Am J Cardiol
Widespread vascular production of C-reactive protein (CRP) and a relationship between serum CRP, plaque CRP, and intimal hypertrophy
Atherosclerosis
Clinical factors, but not C-reactive protein, predict progression of calcific aortic-valve disease: the Cardiovascular Health Study
J Am Coll Cardiol
C-reactive protein to identify early risk for development of calcific aortic stenosis
J Am Coll Cardiol
Characterization of the early lesion of “degenerative” valvular aortic stenosis: histological and immunohistochemical studies
Circulation
Cited by (22)
Factors associated with the progression of aortic valve calcification in older adults
2023, International Journal of CardiologyCalcific aortic stenosis and its correlation with a novel inflammatory marker, the lymphocyte/monocyte ratio
2016, Revista Portuguesa de CardiologiaCitation Excerpt :Inflammation plays an important role in the development and progression of both aortic sclerosis and calcification.3,4 This is reinforced by the observation that interventions that decrease exposure to inflammation have the potential to alleviate progressive stenosis in the aortic valve.4 Therefore, the identification of inflammatory markers implicated in CAS can potentially be helpful in assessing the progression as well as the severity of the disease.
Biomarkers of aortic valve stenosis: Should we rely on a single one?
2016, Revista Portuguesa de CardiologiaC-reactive protein and endothelial dysfunction: Gazing at the coronaries
2011, International Journal of CardiologyCitation Excerpt :Genetic data have questioned the causal role of CRP in atherogenesis [12] and its' predictive role of future CVD events in patients with peripheral artery disease [13] as well as its' contribution to aortic calcification [14]. Additionally, it is worth mentioning the controversial results regarding the predictive value as regards clinical outcomes/atherogenesis [15] and arterial restenosis in patients undergoing percutaneous coronary intervention (PCI) [2]. Finally, data from the Heart Protection Study [16] have reported that baseline CRP concentration does not modify the vascular benefits of statin therapy, in controversy to the JUPITER.
New Trends in the Impact of Periodontal Treatment on Early Cardiovascular Diseases Outcomes: Insights and Future Perspectives
2023, Reviews in Cardiovascular MedicineImpact of C-reactive protein levels on lipoprotein(a)-associated aortic stenosis incidence and progression
2023, European Heart Journal Open